Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases Business Wire Nawigacja wpisu Enhanced dynamic risk stratification of smoldering multiple myeloma – Nature College of Medicine celebrates 100% match rate for Class of 2026 – University of Cincinnati
